Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for abuse of dominant position
US Copyright Office advises not to introduce ancillary copyright protection for press publishers in the US US Copyright Office advises not to introduce ancillary copyright protection for press publishers in the US Reviewed by Eleonora Rosati on Monday, July 04, 2022 Rating: 5
Around the IP Blogs! Around the IP Blogs! Reviewed by Verónica Rodríguez Arguijo on Sunday, September 17, 2017 Rating: 5
Around the IP Blogs! Around the IP Blogs! Reviewed by Verónica Rodríguez Arguijo on Tuesday, April 25, 2017 Rating: 5
BREAKING: Birss J hands down first FRAND decision in Unwired Planet v Huawei BREAKING: Birss J hands down first FRAND decision in Unwired Planet v Huawei Reviewed by Annsley Merelle Ward on Wednesday, April 05, 2017 Rating: 5
Shock ruling by top European Court: enforcing a patent is an abuse of process, except where it isn't Shock ruling by top European Court: enforcing a patent is an abuse of process, except where it isn't Reviewed by Jeremy on Thursday, July 16, 2015 Rating: 5
Wah-the-ley on Wah-way: a matter of Opinion Wah-the-ley on Wah-way: a matter of Opinion Reviewed by Jeremy on Tuesday, November 25, 2014 Rating: 5
Huawei: the Duesseldorf court presumes to ask Huawei: the Duesseldorf court presumes to ask Reviewed by Jeremy on Wednesday, May 22, 2013 Rating: 5
Feeling fine? Europe enriched by AstraZeneca's millions Feeling fine? Europe enriched by AstraZeneca's millions Reviewed by Jeremy on Thursday, December 06, 2012 Rating: 5
One in the eye for Pfizer glaucoma patent policy? One in the eye for Pfizer glaucoma patent policy? Reviewed by Catherine Lee on Tuesday, February 14, 2012 Rating: 5
Is STIM a bully? It all depends ... Is STIM a bully? It all depends ... Reviewed by Jeremy on Tuesday, December 30, 2008 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.